These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9762687)

  • 21. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis of oligodendrocytes and post-translational modifications of myelin basic protein in multiple sclerosis: possible role for the early stages of multiple sclerosis.
    Artemiadis AK; Anagnostouli MC
    Eur Neurol; 2010; 63(2):65-72. PubMed ID: 20068323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis.
    Villoslada P; Baranzini S
    J Neuroimmunol; 2012 Jul; 248(1-2):58-65. PubMed ID: 22281286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies.
    McFarland HF; Stone LA; Calabresi PA; Maloni H; Bash CN; Frank JA
    Mult Scler; 1996 Nov; 2(4):198-205. PubMed ID: 9345374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy monitoring in patients with multiple sclerosis based on transcriptomic analysis].
    Zettl UK; Goertsches RH
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S64-8. PubMed ID: 19685398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
    Chowdhury SA; Lin J; Sadiq SA
    Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.
    Sharief MK; Hentges R
    N Engl J Med; 1991 Aug; 325(7):467-72. PubMed ID: 1852181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis.
    Sellebjerg F; Christiansen M; Nielsen PM; Frederiksen JL
    Mult Scler; 1998 Dec; 4(6):475-9. PubMed ID: 9987755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis.
    Calabrese V; Raffaele R; Cosentino E; Rizza V
    Int J Clin Pharmacol Res; 1994; 14(4):119-23. PubMed ID: 7607784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)].
    Fernández-Fernández O; Alvarez-Cermeño JC; Arbizu-Urdiain T; Arroyo-González R; Arnal-García C; Casanova-Estruch B; Calles-Hernández MC; Coret-Ferrer F; Comabella M; García-Merino JA; de Las Heras V; Izquierdo G; Meca-Lallana JE; Muñoz-García D; Olascoaga J; Oreja-Guevara C; Prieto JM; Rodríguez-Antigüedad A; Tintoré M; Montalban X;
    Rev Neurol; 2011 Feb; 52(4):227-38. PubMed ID: 21312169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unresolved issues in the analysis of F2-isoprostanes, F4-neuroprostanes, isofurans, neurofurans, and F2-dihomo-isoprostanes in body fluids and tissue using gas chromatography/negative-ion chemical-ionization mass spectrometry.
    Yen HC; Wei HJ; Lin CL
    Free Radic Res; 2015; 49(7):861-80. PubMed ID: 25812589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force.
    Miller DH
    Mult Scler; 1996 Jul; 1(6):335-8. PubMed ID: 9345412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid analysis in multiple sclerosis.
    Luque FA; Jaffe SL
    Int Rev Neurobiol; 2007; 79():341-56. PubMed ID: 17531849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dynamic stabilometry as a monitoring of movement and coordination disorders in the rehabilitation of patients with multiple sclerosis].
    Popova NF; Shagaev AS; Demina TL; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):35-9. PubMed ID: 19156084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis.
    Filippi M; Horsfield MA; Adèr HJ; Barkhof F; Bruzzi P; Evans A; Frank JA; Grossman RI; McFarland HF; Molyneux P; Paty DW; Simon J; Tofts PS; Wolinsky JS; Miller DH
    Ann Neurol; 1998 Apr; 43(4):499-506. PubMed ID: 9546332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
    Dagley LF; Emili A; Purcell AW
    Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple sclerosis: use of MRI in evaluating new therapies.
    Miller DH
    Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood, sweat, and tears: developing clinically relevant protein biosensors for integrated body fluid analysis.
    Corrie SR; Coffey JW; Islam J; Markey KA; Kendall MA
    Analyst; 2015 Jul; 140(13):4350-64. PubMed ID: 25909342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.
    García-Merino A; Fernández O; Montalbán X; de Andrés C; Oreja-Guevara C; Rodríguez-Antigüedad A; Arbizu T;
    Neurologia; 2013; 28(6):375-8. PubMed ID: 23643683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.